Intra-Cellular Therapies, Inc.

NasdaqGS ITCI

Intra-Cellular Therapies, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 166.11 M

Intra-Cellular Therapies, Inc. Current Liabilities is USD 166.11 M for the quarter ending September 30, 2024, a 61.13% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Intra-Cellular Therapies, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 103.09 M, a 33.18% change year over year.
Intra-Cellular Therapies, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 77.41 M, a 55.14% change year over year.
Intra-Cellular Therapies, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 49.90 M, a 31.20% change year over year.
Intra-Cellular Therapies, Inc. Current Liabilities for the quarter ending September 30, 2020 was USD 38.03 M, a 13.95% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqGS: ITCI

Intra-Cellular Therapies, Inc.

CEO	Dr. Sharon Mates Ph.D.
IPO Date	Jan. 7, 2014
Location	United States
Headquarters	430 East 29th Street
Employees	610
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health

Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Key trends

Past 5 years